CASE REPORT

A case of severe psychosis induced by novel recreational drugs
[version 1; referees: 2 approved]

Filippo Dragogna, Lucio Oldani, Massimiliano Buoli, A. Carlo Altamura
Department of Psychiatry, University of Milan, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

Abstract

**Introduction:** The use of novel recreational drugs is becoming of public interest, especially after recent international alerts about their cardiovascular and neurological toxicity. Additionally, little is known about the psychiatric consequences of the long-term use of these compounds.

**Case presentation:** We describe a case of a severe psychotic episode likely induced by chronic use of a combination of new recreational drugs (methylene-dioxypyrvalerone, mephedrone, butylone and alpha-pyrrolidinopentiophenone). The patient had no psychiatric history and showed poor response to conventional antipsychotic treatment (haloperidol).

**Conclusions:** This case illustrates the potential negative effects of recreational drugs that cannot be limited to an acute psychotic episode but might determine a condition of prolonged paranoid psychosis. Although the use of these compounds is currently increasing, such molecules might often pass undetected in patients accessing the emergency room, leading to misdiagnosis (e.g. schizophrenic episode) and lack of appropriate treatment.

Corresponding author: Lucio Oldani (lucio.oldani@gmail.com)

How to cite this article: Dragogna F, Oldani L, Buoli M and Altamura AC. A case of severe psychosis induced by novel recreational drugs [version 1; referees: 2 approved] F1000Research 2014, 3:21 (doi: 10.12688/f1000research.3-21.v1)

Copyright: © 2014 Dragogna F et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Competing interests: Prof. A. Carlo Altamura is a Merck consultant, Astra Zeneca consultant, Sanofi-Aventis speaker’s bureau member, Lilly speaker’s bureau member, Pfizer speaker’s bureau member and a Roche consultant. Dr Buoli is a Roche consultant. Dr Dragogna and Dr Oldani have no competing interests to disclose.

Case description
We report the case of a 46-y.o. Italian Caucasian man (1.70 m, 70 kg), working as a full-time legal consultant.

He was brought to the emergency room of our Psychiatric Department in 2013, after having ingested a large quantity of zolpidem, a prescription drug indicated for insomnia, with suicidal intent. His family history was negative for psychiatric disorders, but he presented a positive medical history for liver disease (active chronic hepatitis C and Gilbert’s syndrome). He had never suffered from any psychiatric symptoms in his childhood, adolescence or early adulthood. He had no family history of psychiatric disorders.

The patient’s psychopathological onset occurred three months prior to admission when, after continuous use (from one to three times a week) of a non-specified recreational drug since July 2012, provided to him by a friend who used to buy it online. He developed a persecutory delusion, characterized by the conviction of being spied upon by some unknown people who placed video cameras around his house. In addition, he believed that sexual activity he had with his wife was being filmed and then spread on pornographic websites. For this reason, in the following weeks, he made a written complaint against unknown persons and presented it to the local police office. In addition, one night he called the police force to his own home, as he saw suspicious movements outside his window. On that occasion, the police found out that the patient had a gun, which was then confiscated due to security concerns. Thus, the police then became part of patient’s delusional plot: the patient started thinking his daughter was involved in prostitution and he blamed the police for that. These events, along with two formal warnings received from his employer (since he did not show up for work for many days in a row), and a prolonged condition of global insomnia, generated a state of severe discouragement and embarrassment in the patient. On account of this he attempted suicide by ingesting a large quantity of zolpidem tablets (about 40 tablets of 10 mg, as related by the patient himself). Zolpidem had been prescribed four months prior to admission by a general practitioner to treat the patient’s insomnia.

In the emergency room of our hospital, the patient was initially drowsy and slow in his movements, although he was eupneic and had stable vital parameters. He underwent a physical examination, an electrocardiogram, a chest X-ray and a brain computer tomography, which were all normal. Though initially considered appropriate, no gastric lavage with activated charcoal was conducted as the laboratory (PET) was performed on the 10th day of admission, which showed some unspecific findings consisting of an increased glucose metabolism in the basal nuclei but normal levels in the cortical regions.

During the hospitalization period, a sample of the drug the patient had used for some months, in the form of white powder, was found at his home and delivered to the medical staff. This powder sample, along with further blood and urine samples, were sent to the Legal Medicine laboratory in the Forensic Toxicology section of our University, after having obtained a regular written consent from the patient. A specific analysis on the three samples was conducted by means of gas chromatography/mass spectrometry and liquid chromatography/high resolution mass spectrometry. The following molecules were found by the analysis on the powder: methylenedioxypyrovalerone, mephedrone, butylone and alpha-pyrrolidinopen-tiophenone (a-PVP) (the proportion of the each was not provided by the laboratory) (Table 1). Traces of methylenedioxypyrovalerone were found in the urine sample. A test for psychotropic drugs gave negative results for the blood sample.

With regards to the psychopharmacological therapy, since the beginning of his hospitalization the patient was treated with haloperidol 5 mg daily, showing an overall good medication adherence although his response was very poor. For this reason, we decided to administer an injection of haloperidol decanoate at a dosage of 150 mg (to be repeated every 4 weeks, as part of an outpatient regimen). One month after his discharge, in a follow-up visit, the patient showed a BPRS score of 29, corresponding to a slight improvement in persecutory delusion but no change in insight.

Discussion
In contrast to other reports that show hallucinatory delirium, agitation, anxiety and sleep disturbances following an acute intake of more popular substances of abuse (e.g. cannabis, cocaine), we describe a clinical picture of a persistent substance-induced psychosis, secondary to a prolonged intake of methylenedioxypyrovalerone, mephedrone, butylone and alpha-pyrrolidinopen-tiophenone (a-PVP). The correlation of symptoms with the intake of these substances is supposed in the light of a negative psychiatric history and no concomitant medical treatments. Of note, increased glucose metabolism in the basal nuclei at PET was probably due to the effects of haloperidol than to the substances, as documented.
by other reports. In addition, the moderate hepatic failure of the patient could be responsible for the increased availability of the drugs and increased toxicity, as hepatic metabolism is involved in the excretion of all these substances.

The present report shows the danger of these novel drugs that are often bought as apparently safe and legal on the internet. However, a number of case reports have documented deaths related to the ingestion of such substances, especially for mephedrone and methylenedioxypyrovalerone. A further problem is that these substances are not detected by standard blood and urine tests so that the diagnosis of intoxication is often delayed. This means that patients may not receive the appropriate treatment due to the lack of diagnostic tools and may be misdiagnosed as schizophrenic or manic bipolar patients. This issue is particularly relevant in the emergency department, where a fast and precise diagnosis and management of patients is required. In addition, patients leaving the emergency department without being correctly diagnosed might continue their abuse and delay specialized follow-up visits in an outpatient context, finally developing a condition of chronic treatment-resistant psychosis.

These drugs are very popular among young clubbers and mephedrone was reported as the sixth most commonly used drug after alcohol, tobacco, cannabis, MDMA and cocaine in the dance music scene, night clubs and gay bars. Educational campaigns about the risks related to these substances are needed in light of the negative effects that can be sustained over time. In addition, clinical pictures similar to the one described should not be confused with schizophrenic episodes despite the atypical presentation and good pre-morbid social functioning.

**Consent**

Consent was obtained from the patient for use of their information for publication in this article.

**Author contributions**

Dr Dragogna and Dr Oldani followed the case and wrote the case report. Dr Buoli revised the paper and constructed the table. Professor Altamura revised the paper. All authors agreed the final version of the manuscript for publication.

**Competing interests**

Prof. A. Carlo Altamura is a Merck consultant, Astra Zeneca consultant, Sanofi-Aventis speaker’s bureau member, Lilly speaker’s bureau member, Pfizer speaker’s bureau member and a Roche consultant. Dr Buoli is a Roche consultant. Dr Dragogna and Dr Oldani have no competing interests to disclose.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

---

**Table 1. Summary of pharmacological components present in the white powder taken by the patient.**

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Mechanism of action</th>
<th>Effects</th>
<th>Potential risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylenedioxypyrovalerone</td>
<td>Norepinephrine-dopamine reuptake inhibitor</td>
<td>Psychic: euphoria, increased wakefulness (severe insomnia) Physical: tachycardia, hypertension</td>
<td>Hyperthermia (^3,4^)</td>
</tr>
<tr>
<td>Mephedrone</td>
<td>Serotonin-dopamine reuptake inhibitor, pre-synaptic monoamine release</td>
<td>Psychic: elevated mood, hallucinations, delusions, sexual stimulation Physical: tachycardia, hypertension, breath depression, increased sweating, teeth grinding</td>
<td>Stroke, heart failure, hyperthermia</td>
</tr>
<tr>
<td>Butylone</td>
<td>Dopamine reuptake inhibitor, serotonin receptor 2A agonist</td>
<td>Psychic: mild euphoria Physical: nystagmus, increased body temperature, teeth grinding</td>
<td>Rhabdomyolysis, hyperthermia, acute renal failure</td>
</tr>
<tr>
<td>Alpha-Pyrrolidinopentiophenone (a-PVP)</td>
<td>Norepinephrine-dopamine reuptake inhibitor</td>
<td>Psychiatric: euphoria, anxiety Physical: tachycardia, hypertension</td>
<td>Hyperthermia</td>
</tr>
</tbody>
</table>

---


Open Peer Review

Current Referee Status: ✔ ✔

Version 1

Referee Report 13 October 2014

doi:10.5256/f1000research.3458.r6396

George Woody
Treatment Research Institute, University of Pennsylvania, Philadelphia, PA, USA

This is an interesting case report that is clearly written and documents an instance in which a persistent and treatment resistant psychotic disorder developed after taking an unknown amount of hallucinogenic and stimulant drugs. This case differs from the typical course of substance induced psychoses in that it did not resolve with abstinence and pharmacotherapy. I have no suggestions for modifications.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Referee Report 06 March 2014

doi:10.5256/f1000research.3458.r3493

John Mendelson
Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, USA

Dragogna and colleagues describe a case of persistent psychosis associated with the ingestion of mephadrone and related compounds. These cathinone derivatives have similar risks as other phenethylamine stimulants such as methamphetamine and MDMA and are widely available and easily abused. It is therefore not surprising that persistent psychosis, as described in this case report, can be seen with prolonged use.

Although the authors show an association of cathinone use with admission for a persistent psychosis the relationship between cathinone abuse and the development of psychosis is less clear - this patient may have become psychotic well before using any illicit drugs. However, the case report makes the essential point that urine drug screens with currently available immunoassay are likely to miss cathinone-like drugs. Thus, if cathinone use is suspected, a laboratory work up of biospecimes will need to be performed by groups specializing in medical toxicology. Due to the increasing abuse of drugs in this class clinicians can expect to see more toxicity. Overall, this report adds to the literature.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.